Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Presentation (January 2026)
12 slides from Orion Oyj Class A's investor presentation, January 2026
Slide 1: Building shareholder value - Orion as an investment
Building shareholder value - Orion as an investment
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Orion today – building well-being since 1917
Orion today – building well-being since 1917 Diversified R&D focus in pharmaceutical company oncology and pain Operations in more ~4,000 employees than 35 countries Net sales1 EUR 1,542 million Impacting millions of Operating profit1 417 million lives globally 3 Investor Presentation © Orion Corpora
Slide 4: Our diversified and balanced businesses
Our diversified and balanced businesses Innovative Generics and Branded Products Animal Health Fermion Medicines Consumer Health Respiratory Companion API Portfolio CNS 300+ products animals & manufacturing highlights Women’s Health livestock & CDMO Nordics & Geographies Global Europe & APAC Global
Slide 5: With strong track record in delivering financial results, we have entered a new growth era
With strong track record in delivering financial results, we have entered a new growth era Net sales Operating profit (EUR million) (EUR million) +7.2% 1,542 500 1,600 130 +7.8% 440 1,400 1,341 417 1,190 1,194 400 -6.3% 1,200 228 1,078 30 1,108 1,051 1,041 130 324 45 28 130 228 304 1,000 300 280 275
Slide 6: Financial objectives
Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8%1 To grow faster than net sales1,2 Equity ratio Return on equity (ROE) ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 1 Base year 2023 6 Investor Presentation © Orion Corporation 2 Without EUR
Slide 7: Investment case – key themes
Investment case – key themes GROWTH CAPITAL ALLOCATION STABILITY PRIORITIES Innovative Medicines business division Branded Products, Generics and Consumer Innovation driving the growth – currently with Nubeqa® Health, and Animal Health business divisions are the rock-solid base of Orion. Growth oppo
Slide 8: Orion's key clinical development pipeline
Orion’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication (or modality for pre-clinical assets) Preclinical Phase I Phase II Phase III ARASTEP (darolutamide) BCR (prostate cancer) DASL-HiCaP (darolutamide) (Neo-)Adjuvant prostate cancer OMAHA-003 (opevesostat) (lat
Slide 9: Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer
Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer ODM-212 has anti- ODM-212 has resistance- tumour activity prevention activity Cancers driven by the Hippo pathway Prevention of cancer treatment resistance Targeting solid tumours with Hippo in which TEAD activation is limit
Slide 10: Orion's journey and commitment to oncology
Orion’s journey and commitment to oncology 2024 Nubeqa® Reaches blockbuster status 2026e 2011 2018 2023 2023 2025 ODM-212 Nubeqa® Opevesostat 2019 IO 2020 ADC Opevesostat ODM-212 ODM-212 Phase II in (Darolutamide) Phase I/II in Research in Research In 2x Phase III Phase I in Phase II in combination
Slide 11: Outlook for 2026
Outlook for 2026 Net sales EUR 1,900 million–EUR 2,100 million Operating profit EUR 550 million–EUR 750 million 11 Investor Presentation © Orion Corporation
Slide 12: Q&A
Q&A 12 Investor Presentation © Orion Corporation